Stocks to buy

They call it FUD: fear, uncertainty and doubt. Based in China, ride-hailing giant Didi Global (NYSE:DIDI) has its fair share of problems, I’ll admit. But there’s also plenty of FUD surrounding DIDI stock. Source: Piotr Swat / Shutterstock.com For example, reports recently circulated claiming that China’s Beijing city government advised state-owned companies to invest in the
0 Comments
ViacomCBS (NASDAQ:VIAC) has been a costly disappointment for some investors in 2021. Enthusiasm over the company’s newly-announced streaming plans paired with Reddit-fueled retail investors drove VIAC stock past $100 three weeks into March. That was a 174% gain in under four months. Source: Jer123 / Shutterstock.com A catastrophic crash then saw shares lose half their
0 Comments
Here’s a rare opportunity for you. A “next-generation Medicare Advantage insurer,” Clover Health (NASDAQ:CLOV) operates in a high-potential market, providing health care access to seniors and other patient demographics. Yet, CLOV stock is trading at a surprisingly low price. Source: Shutterstock Currently, this stock has landed gently at a strong support level. So, it might be
0 Comments
The market has experienced increased volatility over the last few weeks. Investors are still nervous about COVID and inflation, plus new issues including the debt ceiling debate and a possibility of an Evergrande default in China. At times like these, investors may look to lower their risk profile.  One way to do that is to
0 Comments
The coronavirus pandemic disrupted many businesses and was a boon to others. One sector that’s been riding high is the pharmaceutical industry. That’s especially true for companies that have brought a Covid-19 vaccine to market. Vaccine developer Novavax (NASDAQ:NVAX) is a perfect example. NVAX stock rose from relative obscurity with a share price of just
0 Comments
Nvidia’s (NASDAQ:NVDA) core businesses have been firing on all cylinders, and its move into other profitable verticals has resulted in consistent top-line growth.  The company’s market value has grown at an incredible pace over the past decade. Yet, NVDA stock still has a ton of upside left with new catalysts that will amplify growth in
0 Comments
Biotech stocks are infamously one of the most volatile sectors in the stock market. Investors often venture into speculative companies with no proven pipelines. Emerging firms with a pipeline of drugs and products still in the clinical phase post little to no revenue. They raise cash by tapping capital markets to pay for research and
0 Comments